Horizon Therapeutics Public Form 4 / Andy Pasternak ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Pasternak Andy

(Last)

(First)

(Middle)

C/O HORIZON THERAPEUTICS PLC,

70 ST. STEPHEN?S GREEN

(Street)

DUBLIN

D02 E2X4

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Horizon Therapeutics Public Ltd Co [ HZNP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
EVP, Chief Strategy Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/06/2023

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	10/06/2023		D		56,338	D	$116.5⁽¹⁾	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽²⁾	10/06/2023		D			11,643	⁽³⁾	⁽³⁾	Ordinary Shares	11,643	⁽⁴⁾	0	D
Restricted Stock Units	⁽²⁾	10/06/2023		D			15,870	⁽⁵⁾	⁽⁵⁾	Ordinary Shares	15,870	⁽⁴⁾	0	D
Restricted Stock Units	⁽²⁾	10/06/2023		D			22,997	⁽⁶⁾	⁽⁶⁾	Ordinary Shares	22,997	⁽⁴⁾	0	D
Performance Restricted Stock Units	⁽²⁾	10/06/2023		D			15,281	⁽⁷⁾	⁽⁷⁾	Ordinary Shares	15,281	⁽⁸⁾	0	D
Performance Restricted Stock Units	⁽²⁾	10/06/2023		D			5,816	⁽⁷⁾	⁽⁷⁾	Ordinary Shares	5,816	⁽⁸⁾	0	D
Performance Restricted Stock Units	⁽²⁾	10/06/2023		D			34,928	⁽⁷⁾	⁽⁷⁾	Ordinary Shares	34,928	⁽⁸⁾	0	D
Performance Restricted Stock Units	⁽²⁾	10/06/2023		D			4,761	⁽⁹⁾	⁽⁹⁾	Ordinary Shares	4,761	⁽⁸⁾	0	D
Performance Restricted Stock Units	⁽²⁾	10/06/2023		D			14,282	⁽¹⁰⁾	⁽¹⁰⁾	Ordinary Shares	14,282	⁽⁸⁾	0	D
Performance Restricted Stock Units	⁽²⁾	10/06/2023		D			23,806	⁽¹⁰⁾	⁽¹⁰⁾	Ordinary Shares	23,806	⁽⁸⁾	0	D
Performance Restricted Stock Units	⁽²⁾	10/06/2023		D			11,499	⁽¹¹⁾	⁽¹¹⁾	Ordinary Shares	11,499	⁽⁸⁾	0	D
Performance Restricted Stock Units	⁽²⁾	10/06/2023		D			5,749	⁽¹²⁾	⁽¹²⁾	Ordinary Shares	5,749	⁽⁸⁾	0	D
Performance Restricted Stock Units	⁽²⁾	10/06/2023		D			5,749	⁽¹²⁾	⁽¹²⁾	Ordinary Shares	5,749	⁽⁸⁾	0	D

Explanation of Responses:

1. Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration").

2. Each RSU (as defined in footnote 4 to this Form 4) and PSU (as defined in footnote 8 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer.

3. The Ordinary Shares subject to the RSUs vest on January 5, 2024.

4. Reflects the disposition of Issuer's restricted stock unit awards, excluding PSUs (as defined in footnote 8 to this Form 4), (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was assumed and converted into a restricted stock unit (each, a "Parent RSU") denominated in shares of Parent's common stock. The number of shares of Parent's common stock subject to each such Parent RSU was equal to the product (rounded down to the nearest whole number) of (y) the number of shares of Ordinary Shares subject to the RSU immediately prior to the Effective Time multiplied by (z) the ratio equal to (1) the Consideration divided by (2) the volume weighted average of the per share closing price of Parent's common stock on the Nasdaq for five (5) trading days ending on the second business day prior to the completion of the Scheme.

5. The Ordinary Shares subject to the RSUs vest 1/3rd annually on each anniversary of January 5, 2022.

6. The Ordinary Shares subject to the RSUs vest 1/3rd annually on each anniversary of January 5, 2023.

7. The Ordinary Shares subject to the PSUs (as defined in footnote 8 to this Form 4) vest on January 5, 2024.

8. Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration.

9. The Ordinary Shares subject to the PSUs vest 2/3rd on January 5, 2024 and the remaining shares vest on January 5, 2025.

10. The Ordinary Shares subject to the PSUs vest on January 5, 2025.

11. The Ordinary Shares subject to the PSUs vest on January 5, 2026.

12. The Ordinary Shares subject to the PSUs vest 2/3rd on January 5, 2025 and the remaining shares vest on January 5, 2026.

Remarks:

	/s/ Patrick McIlvenny, Attorney-in-Fact	10/06/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Horizon Therapeutics Public (HZNP) Form 4Horizon Therapeutics Public / Andy Pasternak ownership change